Trinity Biotech is developing a new continuous glucose monitor called CGM+. Instead of focusing only on glucose, the wearable uses proprietary needle-free sensor technology that could allow for expanded tracking from a single modular wearable device. Future versions could track heart signals, sleep, movement, and temperature. Trinity’s CEO John Gillard says “CGM+ is not just a device—it’s a proprietary data engine we are building for the AI health ecosystem.”
So far, only the glucose tracking has been tested, with detailed results expected soon. A pre-pivotal trial confirmed 15-day wear without the need for fingerstick calibrations. CGM+ uses fewer disposable parts thanks to its reusable applicator which could mean lower cost and better sustainability than competitors.
CGM+ modular wearables with reusable applicator and companion app. (Source: Trinity Biotech)
Trinity says CGM+ is meant to grow into a platform, not just a sensor. Which means down the line, CGMs could shift from single-purpose diabetes tools to full-on health hubs.
Trinity is not alone in developing a multi-analyze sensor—SAVA is developing its own needle-free CGM that could measures a list of vitals and Abbott is working on a dual glucose-ketone sensor it already has insulin pump partners for.
(Source: Trinity Biotech)
Trinity Biotech plans to submit it to the FDA in 2026 and launch later that year. Whether this makes it to consumers or not, I expect exciting days ahead for the future of CGMs.